Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.
about
Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure.
P2860
Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Single low-dose rHuIL-12 safel ...... c and immune-mediated effects.
@en
Single low-dose rHuIL-12 safel ...... c and immune-mediated effects.
@nl
type
label
Single low-dose rHuIL-12 safel ...... c and immune-mediated effects.
@en
Single low-dose rHuIL-12 safel ...... c and immune-mediated effects.
@nl
prefLabel
Single low-dose rHuIL-12 safel ...... c and immune-mediated effects.
@en
Single low-dose rHuIL-12 safel ...... c and immune-mediated effects.
@nl
P2093
P2860
P356
P1476
Single low-dose rHuIL-12 safel ...... c and immune-mediated effects.
@en
P2093
Chris E Lawrence
Lena A Basile
Mamata S Gokhale
Nicholas Siebers
Simmy Thomas
Vladimir Vainstein
Zoya Gluzman-Poltorak
P2860
P2888
P356
10.1186/2162-3619-3-11
P577
2014-04-11T00:00:00Z
P5875
P6179
1008590933